Logo do repositório
 
Publicação

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies

2020-04-07Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorCalado, Rita
dc.contributor.authorDuarte, Joana
dc.contributor.authorBorrego, Pedro
dc.contributor.authorMarcelino, José Maria
dc.contributor.authorBártolo, Inês
dc.contributor.authorMartin, Francisco
dc.contributor.authorFigueiredo, Inês
dc.contributor.authorAlmeida, Sílvia
dc.contributor.authorGraça, Luis
dc.contributor.authorVítor, Jorge M. B.
dc.contributor.authorSilva, Frederico Aires da
dc.contributor.authorDias, Inês
dc.contributor.authorCarrapiço, Belmira
dc.contributor.authorTaveira, Nuno
dc.date.accessioned2023-08-14T17:50:14Z
dc.date.available2023-08-14T17:50:14Z
dc.date.issued2020-04-07
dc.date.updated2022-10-19T21:41:37Z
dc.description.abstractDevelopment of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. Mice primed with the recombinant Vaccinia viruses and boosted with the homologous gp120t or C2V3C3 polypeptides developed antibodies that bind potently to homologous and heterologous envelope glycoproteins. Notably, a subset of mice immunized with the CRF02_AG-based envelope immunogens developed a cross-reactive neutralizing response against tier 2 HIV-1 Env-pseudoviruses and primary isolates. Rabbits vaccinated with the CRF02_AG-based envelope immunogens also generated potent binding antibodies, and one animal elicited antibodies that neutralized almost all (13 of 16, 81.3%) tier 2 HIV-1 isolates tested. Overall, the results suggest that the novel CRF02_AG-based envelope immunogens and prime-boost immunization strategy elicit the type of immune responses required for a preventive HIV-1 vaccine.pt_PT
dc.description.sponsorshipThis research was funded by the Genese Program, Gilead Sciences, Portugal (grants PGG/015/2016 to F.A.S. and PGG/02/2015 to N.T.). Francisco Martin and Rita Calado were funded by PhD fellowships (SFRH/BD/87488/2012; SFRH/BD/70715/2010) from Fundação para a Ciência e Tecnologia (FCT), Portugal. Inês Bártolo was funded by a post-doc fellowship (SFRH/BPD/76225/2011) from Fundação para a Ciência e Tecnologia (FCT), Portugal. José M. Marcelino was funded by a post-doc fellowship from FCT and Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in Portuguese speaking countries in Africa (Project reference: 332821690). Nuno Taveira was partially funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), UE (LIFE project, reference RIA2016MC-1615).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationCalado R, Duarte J, Borrego P, Marcelino JM, Bártolo I, Martin F, et al. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines [Internet]. 2020 Apr 7;8(2):171. Available from: http://dx.doi.org/10.3390/vaccines8020171pt_PT
dc.identifier.doi10.3390/vaccines8020171pt_PT
dc.identifier.issn2076-393X
dc.identifier.slugcv-prod-1829734
dc.identifier.urihttp://hdl.handle.net/10451/58874
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationPGG/015/2016pt_PT
dc.relationHIV EPIDEMIOLOGY AND PATHOGENESIS IN WOMEN AND CHILDREN IN LUANDA, ANGOLA
dc.relationDEVELOPMENT AND PRE-CLINICAL EVALUATION OF A NEW HIV-1 VACCINE CONCEPT
dc.relationDESENVOLVIMENTO DE NOVOS MICROBICIDAS PARA PREVENIR A INFECÇÃO POR VIH
dc.relation.publisherversionhttps://www.mdpi.com/2076-393X/8/2/171pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectHIV-1 vaccinept_PT
dc.subjectRecombinant Vaccinia viruspt_PT
dc.subjectEnvelope glycoproteinspt_PT
dc.subjectnon-B-non-C cladespt_PT
dc.subjectBALB/c micept_PT
dc.subjectNew Zealand White rabbitspt_PT
dc.subjectBroadly neutralizing antibodiespt_PT
dc.titleA Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodiespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleHIV EPIDEMIOLOGY AND PATHOGENESIS IN WOMEN AND CHILDREN IN LUANDA, ANGOLA
oaire.awardTitleDEVELOPMENT AND PRE-CLINICAL EVALUATION OF A NEW HIV-1 VACCINE CONCEPT
oaire.awardTitleDESENVOLVIMENTO DE NOVOS MICROBICIDAS PARA PREVENIR A INFECÇÃO POR VIH
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F87488%2F2012/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F70715%2F2010/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBPD%2F76225%2F2011/PT
oaire.citation.issue2pt_PT
oaire.citation.startPage171pt_PT
oaire.citation.titleVaccinespt_PT
oaire.citation.volume8pt_PT
oaire.fundingStreamOE
person.familyNameAlmeida Calado
person.familyNameduarte
person.familyNameBorrego
person.familyNameMARCELINO
person.familyNameBártolo
person.familyNameMartin
person.familyNameAlmeida
person.familyNameSilva Graca
person.familyNameVítor
person.familyNameAires da Silva
person.familyNameTaveira
person.givenNameRita Diogo
person.givenNamejoana
person.givenNamePedro
person.givenNameJOSÉ MARIA
person.givenNameInês
person.givenNameFrancisco
person.givenNameSílvia
person.givenNameLuis Ricardo
person.givenNameJorge
person.givenNameFrederico Nuno Castanheira
person.givenNameNuno
person.identifierB-3374-2008
person.identifierB-8887-2008
person.identifier.ciencia-idAA18-62FA-B4B3
person.identifier.ciencia-idA71C-0177-722F
person.identifier.ciencia-id7917-FE62-1011
person.identifier.ciencia-id661E-F5CB-F85A
person.identifier.ciencia-idCE1B-02AA-5A3C
person.identifier.ciencia-id6919-698F-C3EF
person.identifier.ciencia-id6C19-B162-F561
person.identifier.ciencia-idFF19-99F4-3964
person.identifier.ciencia-id4410-6DA0-C74C
person.identifier.ciencia-id7111-3383-A926
person.identifier.orcid0000-0002-2519-7917
person.identifier.orcid0000-0002-5736-9138
person.identifier.orcid0000-0002-1949-9484
person.identifier.orcid0000-0002-4597-1535
person.identifier.orcid0000-0002-2022-8921
person.identifier.orcid0000-0002-9599-7805
person.identifier.orcid0000-0002-2400-6090
person.identifier.orcid0000-0001-6935-8500
person.identifier.orcid0000-0001-6486-3444
person.identifier.orcid0000-0002-3821-419X
person.identifier.orcid0000-0003-0176-5585
person.identifier.ridA-6184-2014
person.identifier.ridH-6968-2013
person.identifier.ridL-3171-2014
person.identifier.ridM-3279-2013
person.identifier.scopus-author-id15131150800
person.identifier.scopus-author-id25225039400
person.identifier.scopus-author-id12240839300
person.identifier.scopus-author-id36702640400
person.identifier.scopus-author-id36138488700
person.identifier.scopus-author-id7801493621
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.cv.cienciaidFF19-99F4-3964 | Jorge Manuel Barreto Vítor
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationbca88dd5-4b60-4441-93dd-eddfa6fa50ef
relation.isAuthorOfPublication66f82ae6-718f-4623-b701-d1777149f31d
relation.isAuthorOfPublication64f9a682-4d1d-4bc3-8854-c6673527f871
relation.isAuthorOfPublicationc6e3d8ca-8631-40d0-bdf4-de67e33f3231
relation.isAuthorOfPublicationb5f3db05-baf4-4d91-99c7-581e4c7b2e74
relation.isAuthorOfPublicationdff6de26-4daf-4c2e-9b0f-0b1d9e638cfc
relation.isAuthorOfPublication2051d2c9-aa40-4c5d-9f5a-bc5a001d6219
relation.isAuthorOfPublication9da841d6-508a-484b-a61e-ee2fab2bc226
relation.isAuthorOfPublicationbe15e90f-9cc9-4ad0-b9fd-465236b72e9a
relation.isAuthorOfPublication1b241db4-a815-4339-a2fe-426d501b871c
relation.isAuthorOfPublicationd62b22f8-7ce6-4bb2-ac55-2117707f6612
relation.isAuthorOfPublication.latestForDiscoveryd62b22f8-7ce6-4bb2-ac55-2117707f6612
relation.isProjectOfPublicationd76556b3-f2c0-4f34-b86c-10894b174246
relation.isProjectOfPublication620d35e7-a0c0-439d-a4cc-481cc103b68f
relation.isProjectOfPublicatione3b7c207-d129-4c0c-b2b0-ea8199cad9f8
relation.isProjectOfPublication.latestForDiscoveryd76556b3-f2c0-4f34-b86c-10894b174246

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Calado_et_al._HIV-1_vaccine_Vaccines-08-00171-2020.pdf
Tamanho:
4.63 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FF - CiênciaVitae - Faculdade de Farmácia